Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$7.91 -2.8%	$8.01	$5.20 ▼ $10.67	$1.11B	1.15	1.32 million shs	935,104 shs
ELVN Enliven Therapeutics	$21.80 -5.6%	$18.45	$13.30 ▼ $30.03	$1.13B	0.79	290,579 shs	661,678 shs
NAGE Niagen Bioscience	$13.88 -1.8%	$9.58	$2.31 ▼ $14.49	$1.07B	2.08	890,676 shs	707,549 shs
PROK ProKidney	$0.86 -13.0%	$0.81	$0.46 ▼ $3.00	$245.37M	1.35	625,145 shs	1.16 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-2.83%	-2.94%	-3.42%	-5.50%	+42.78%
ELVN Enliven Therapeutics	-5.59%	+0.46%	+29.30%	+4.36%	+1.11%
NAGE Niagen Bioscience	-1.84%	+2.66%	+26.76%	+79.33%	+365.77%
PROK ProKidney	-13.02%	-14.21%	+6.36%	-13.43%	-70.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.2834 of 5 stars	3.5	2.0	4.1	0.8	1.9
ELVN Enliven Therapeutics	2.4852 of 5 stars	3.5	1.0	2.7	4.2	0.0
NAGE Niagen Bioscience	1.4465 of 5 stars	3.5	0.0	2.5	0.0	0.0
PROK ProKidney	2.4272 of 5 stars	3.2	0.0	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	45.39% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	81.65% Upside
NAGE Niagen Bioscience	3.00	Buy	$19.50	40.49% Upside
PROK ProKidney	2.33	Hold	$4.50	424.54% Upside

Current Analyst Ratings Breakdown

Latest PROK, ELVN, AUPH, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.54	$0.30 per share	26.52	$2.68 per share	2.95
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
NAGE Niagen Bioscience	$99.60M	10.98	$0.06 per share	230.43	$0.60 per share	23.13
PROK ProKidney	$80K	3,138.84	N/A	N/A	($3.41) per share	-0.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	28.25	14.13	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	81.65	∞	N/A	13.07%	19.06%	12.20%	N/A
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest PROK, ELVN, AUPH, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.17	5.60	5.11
ELVN Enliven Therapeutics	N/A	17.44	17.44
NAGE Niagen Bioscience	N/A	N/A	N/A
PROK ProKidney	N/A	17.08	17.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
ELVN Enliven Therapeutics	95.08%
NAGE Niagen Bioscience	15.41%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
ELVN Enliven Therapeutics	25.90%
NAGE Niagen Bioscience	9.39%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
PROK ProKidney	3	292.70 million	171.26 million	Optionable

PROK, ELVN, AUPH, and NAGE Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)

June 8, 2025 | marketbeat.com

ProKidney quarterly loss grows as it nears two key milestones

May 15, 2025 | journalnow.com

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025 | globenewswire.com

Another Big Office Landlord Tests Sales Climate

May 12, 2025 | bankerandtradesman.com

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More

May 9, 2025 | nasdaq.com

Why ProKidney Corp.’s (PROK) Stock Is Down 6.09%

April 28, 2025 | aaii.com

Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

April 25, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 7.90%

April 17, 2025 | aaii.com

ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

April 17, 2025 | insidertrades.com

Greensboro’s Once Great Win Is Now A ProKidney Failure

April 16, 2025 | rhinotimes.com

Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

April 15, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 9.90%

April 10, 2025 | aaii.com

Why ProKidney Corp.’s (PROK) Stock Is Down 14.87%

April 8, 2025 | aaii.com

ProKidney Corp.

March 30, 2025 | wsj.com

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

March 27, 2025 | finance.yahoo.com

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

March 21, 2025 | zacks.com

ProKidney reports larger loss in 2024 as production resumes

March 18, 2025 | journalnow.com

ProKidney reports FY24 EPS (62c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease

March 17, 2025 | quiverquant.com

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

March 17, 2025 | globenewswire.com

Why ProKidney Corp.’s (PROK) Stock Is Down 10.96%

February 26, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, ELVN, AUPH, and NAGE Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.91 -0.23 (-2.83%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$7.96 +0.05 (+0.68%)

As of 08:29 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Enliven Therapeutics NASDAQ:ELVN

$21.80 -1.29 (-5.59%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$21.82 +0.02 (+0.08%)

As of 08:41 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Niagen Bioscience NASDAQ:NAGE

$13.88 -0.26 (-1.84%)

As of 06/17/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

ProKidney NASDAQ:PROK

$0.86 -0.13 (-13.02%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$0.92 +0.06 (+6.89%)

As of 08:36 AM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time